E.g., 06/26/2020
E.g., 06/26/2020
Title Category Credit Event Date Price
Adjuvant Therapy in RCC Podcast (2019)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
AUA Annual Meeting Highlights (2019): Genitourinary Cancer
    • 1.25 AMA PRA Category 1 Credit™
    • 1.25 Non-Physician Participation
$0.00 To better meet the educational needs of urologists and advanced practice providers (APPs), in 2017 the AUA gathered data from a variety of sources, including a comprehensive literature search, as well as membership surveys to determine where gaps exist in knowledge, proficiency, and practice in regards to genitourinary (GU) cancer.
AUA2018 Abstracts and Posters (2018) $0.00 Member only benefit! This is a collection of abstracts presented at the AUA2018.This product does not provide CME.To access abstracts and posters, click REGISTER/TAKE COURSE tab. Then click ENROLL at the bottom of the page.
AUA2018 San Francisco Virtual Meeting (2018) $699.00 NEW for 2018: AUA2018 Virtual Meeting - Members Save $100!Access the latest science from the 2018 AUA Annual Meeting with the AUA2018 VIRTUAL MEETING.The Virtual Meeting provides online access to hundreds of scientific presentations from AUA2018, including:
Chemo-ablation of Upper-Tract Urothelial Carcinoma Podcast (2019)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Clinical Investigations in the Treatment of Urothelial Carcinoma Podcast (2019)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Complex Patient Cases in Bladder Cancer Webcast (2017)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The AUA developed the Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer initiative to include multiple educational interventions to improve the urologist, medical oncologist, and other healthcare provider's ability to care for patients with bladder cancer. These activities are designed to increase the clinician's competence in the application of new and emerging treatment options, including the sequencing and associated side effects of those options.
CPS Muscle Invasive Bladder Cancer (2017)
    • 2.00 AMA PRA Category 1 Credit™
    • 2.00 Non-Physician Participation
$0.00 AUA Guidelines provide a comprehensive and rigorous summary of evidence relating to a variety of disease conditions, providing an indispensable resource for urologic education. The Clinical Problem Solving (CPS) Protocols guideline-based Case Scenarios were designed to help maximize the impact of the guidelines. The purpose of this guideline is to provide a clinical framework for the diagnosis and treatment of muscle invasive bladder cancer (MIBC).
Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer (2017)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The AUA developed the Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer initiative to include multiple educational interventions to improve the urologist, medical oncologist, and other healthcare provider's ability to care for patients with bladder cancer. These activities are designed to increase the clinician's competence in the application of new and emerging treatment options, including the sequencing and associated side effects of those options.
Immune Checkpoint Inhibitors in RCC Podcast (2019)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$0.00 To encourage consistent, high quality, evidence-based treatment of patients, the AUA is launching a series of podcast episodes designed to improve the ability of the urologist to care for patients with prostate, bladder and kidney cancers. These activities are designed to increase the clinician’s competence in the application of new and emerging treatment options, including their mechanism of action and associated side effects.
Life Long Learning Knowledge Assessment Course: Upper Tract Tumors/Urinary Diversion Webcast (2018)
    • 0.50 AMA PRA Category 1 Credit™
    • 0.50 Non-Physician Participation
$99.00 This activity was taken from the 2017 Recertification (MOC) Review Course Webcast: Oncology and Urinary Diversion. The purpose of the AUA Recertification (MOC) Review Course is to prepare attendees for the ABU Recertification Examination. This course will be practice focused and will offer practical and clinically specific updates. It will highlight the AUA guidelines and address general urology practice issues that can be expected on the Recertification Exam.
Life Long Learning Knowledge Assessment Course: Urothelial Bladder Cancer Webcast (2018)
    • 0.75 AMA PRA Category 1 Credit™
    • 0.75 Non-Physician Participation
$99.00 This activity was taken from the 2017 Recertification (MOC) Review Course Webcast: Oncology and Urinary Diversion The purpose of the AUA Recertification (MOC) Review Course is to prepare attendees for the ABU Recertification Examination. This course will be practice focused and will offer practical and clinically specific updates. It will highlight the AUA guidelines and address general urology practice issues that can be expected on the Recertification Exam.
New Muscle Invasive Bladder Cancer Guideline Webcast (2017)
    • 1.00 AMA PRA Category 1 Credit™
    • 1.00 Non-Physician Participation
$0.00 The AUA developed the Emerging Immunotherapeutic Agents for the Treatment of Bladder Cancer initiative to include multiple educational interventions to improve the urologist, medical oncologist, and other healthcare provider's ability to care for patients with bladder cancer. These activities are designed to increase the clinician's competence in the application of new and emerging treatment options, including the sequencing and associated side effects of those options.
Oral Board Study Guide App (iOS and Android) $299.00 The AUA Oral Board Study Guide App features 68 interactive protocols in 34 topic areas. Developed by leading experts in urology, the app has been specifically designed for urologists preparing to take this examination and includes a strong emphasis on AUA Guidelines with direct access to the AUA Guidelines and the AUA Urology Core Curriculum for AUA members. Available for use on Apple and Android devices!
Recertification (MOC) Review Course Webcast: Oncology and Urinary Diversion (2017)
    • 6.50 AMA PRA Category 1 Credit™
    • 6.50 Non-Physician Participation
$1,345.00 Specifically designed for anyone unable to get away from the office to attend the Live Course—the Webcast option delivers the same great content. Purchase of  the Webcast features simultaneous presentation slides and audio recorded from the Live Course and includes access to online course materials.

Pages